--- title: "IAS、MODV 和 TIXT 的最后期限提醒：Frank R. Cruz 律师事务所提醒投资者代表股东提起集体诉讼" description: "弗兰克·R·克鲁兹律师事务所已宣布对 Integral Ad Science (IAS)、ModivCare (MODV) 和 TELUS International (TIXT) 的股东提起集体诉讼。投资者必须在 2025 年 3 月 31 日之前提交首席原告动议。诉讼指控这些公司在其业务运营和财务健康方面发表了误导性声明，影响了股东的投资。遭受损失的股东被鼓励联系该律师事务所寻求帮助" type: "news" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/232111335.md" published_at: "2025-03-17T15:09:28.000Z" --- # IAS、MODV 和 TIXT 的最后期限提醒：Frank R. Cruz 律师事务所提醒投资者代表股东提起集体诉讼 > 弗兰克·R·克鲁兹律师事务所已宣布对 Integral Ad Science (IAS)、ModivCare (MODV) 和 TELUS International (TIXT) 的股东提起集体诉讼。投资者必须在 2025 年 3 月 31 日之前提交首席原告动议。诉讼指控这些公司在其业务运营和财务健康方面发表了误导性声明，影响了股东的投资。遭受损失的股东被鼓励联系该律师事务所寻求帮助 LOS ANGELES, March 17, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com. **Integral Ad Science Holding Corp.** (NASDAQ: IAS) Class Period: March 2, 2023 – February 27, 2024 Lead Plaintiff Deadline: **March 31, 2025** The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that IAS was experiencing a new material trend of increased competitive pricing pressures and that, as a result, IAS had been forced to cut prices to compensate for weakening demand and slowing revenue growth; (2) that IAS’s pricing function was no longer “favorable” and IAS could not sustain its pricing and drive price increases; (3) that pricing had become a key differentiator between IAS and its competitor necessary to close major renewals and new deals; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you are an Integral Ad Science shareholder who suffered a loss, click here to participate. **ModivCare, Inc.** (NASDAQ: MODV) Class Period: November 3, 2022 – September 15, 2024 Lead Plaintiff Deadline: **March 31, 2025** The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) certain contracts used in ModivCare’s NEMT segment caused the Company’s free cash flow to deteriorate; (2) contract renegotiations and pricing accommodations negatively impacted the Company’s adjusted EBITDA; (3) the Company had insufficient liquidity; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you are a ModivCare shareholder who suffered a loss, click here to participate. **TELUS International (Cda) Inc.** (NYSE: TIXT) Class Period: February 16, 2023 – August 1, 2024 Lead Plaintiff Deadline: **March 31, 2025** The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) the Company’s AI Data Solutions offerings required the cannibalization of its higher-margin offerings; (2) that Telus International’s declining profitability was tied to the Company’s drive to develop AI capabilities; (3) that Telus International’s shift toward AI put greater pressure on the Company’s margins than previously disclosed; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you are a TELUS shareholder who suffered a loss, click here to participate. Follow us for updates on Twitter: twitter.com/FRC\_LAW. To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. **Contacts** The Law Offices of Frank R. Cruz, Los Angeles Frank R. Cruz, 310-914-5007 fcruz@frankcruzlaw.com www.frankcruzlaw.com ### Related Stocks - [MODV.US - ModivCare](https://longbridge.com/zh-CN/quote/MODV.US.md) - [MODVQ.US - MODIVCARE INC](https://longbridge.com/zh-CN/quote/MODVQ.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | ModivCare Inc. 註銷其普通股 | ModivCare Inc. 宣佈在第 11 章破產的預先安排的聯合重組計劃下，註銷並退市其普通股。這一舉措導致所有未償還股份被取消，記錄上不再有任何持有者。因此，該公司將不再需要提交定期報告 | [Link](https://longbridge.com/zh-CN/news/271030794.md) | | Quartix Technologies 稱，FRC 已結束對 Quartix 會計處理的審查 | Quartix Technologies PLC：QUARTIX TECHNOLOGIES PLC - FRC 完成對 QUARTIX 會計處理的審查 QUARTIX TECHNOLOGIES PLC - FRC 同意將跟蹤系統歸類為根據 | [Link](https://longbridge.com/zh-CN/news/275565618.md) | --- > **免责声明**：本文内容仅供参考，不构成任何投资建议。